The Centers for Medicare & Medicaid Services (CMS) on Monday announced it will award Merit-Based Incentive Payment System (MIPS) credit to physicians who participate in COVID-19 clinical trials during the 2020 Quality Payment Program (QPP) performance year.
To earn MIPS credit for this new improvement activity, CMS requires that physicians “attest that they participate in a COVID-19 clinical trial utilizing a drug or biological product to treat a patient with a COVID-19 infection and report their findings through a clinical data repository or clinical data registry for the duration of their study.”
The U.S. National Institutes of Health clinical trials website includes a database of privately and publicly funded clinical studies currently being conducted on COVID-19. The CMS website also provides details on clinical studies.
As a reminder, the maximum score for the MIPS improvement activity category is 40 points, which comprises 15% of your overall MIPS final score (0-100 point scale).
The new activity is titled “COVID-19 Clinical Trials” and carries a high weight worth 20 points. However, points for this category double for individual MIPS-eligible clinicians, groups, and virtual groups who hold a qualifying special status. This means physicians who attest to this activity will be awarded half or all of the credit needed to earn the maximum score in this category.
For questions, contact the QPP Service Center at (866) 288-8292 or by email at QPP@cms.hhs.gov. As always, visit the TMA MACRA Resource Center for the latest QPP information.
You also can find the latest news, resources, and government guidance on the coronavirus outbreak by visiting TMA’s COVID-19 Resource Center regularly.
Last Updated On
April 21, 2020